Publicaciones en las que colabora con Juan Macías (18)

2016

  1. Common haplotypes in CD209 promoter and susceptibility to HIV-1 infection in intravenous drug users

    Infection, Genetics and Evolution, Vol. 45, pp. 20-25

2015

  1. Association of complement receptor 2 polymorphisms with innate resistance to HIV-1 infection

    Genes and Immunity, Vol. 16, Núm. 2, pp. 134-141

  2. IFNL4 rs368234815 polymorphism is associated with innate resistance to HIV-1 infection

    AIDS

2014

  1. A polymorphism linked to RRAS, SCAF1, IRF3 and BCL2L12 genes is associated with cirrhosis in hepatitis C virus carriers

    Liver International, Vol. 34, Núm. 4, pp. 558-566

  2. IFNL4 ss469415590 variant shows similar performance to rs12979860 as predictor of response to treatment against hepatitis C virus genotype 1 or 4 in Caucasians

    PLoS ONE, Vol. 9, Núm. 4

2013

  1. A model to predict the response to therapy against hepatitis C virus (HCV) including low-density lipoprotein receptor genotype in HIV/HCV-coinfected patients

    Journal of Antimicrobial Chemotherapy, Vol. 68, Núm. 4, pp. 915-921

  2. Baseline risk factors for relapse in HIV/HCV co-infected patients treated with PEG-IFN/RBV

    Infection, Vol. 41, Núm. 1, pp. 21-26

  3. Effects of the genetic pattern defined by low-density lipoprotein receptor and IL28B genotypes on the outcome of hepatitis C virus infection

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 32, Núm. 11, pp. 1427-1435

  4. Pegylated interferon plus ribavirin is suboptimal inIL28B CC carriers without rapid response

    Journal of Infection, Vol. 67, Núm. 1, pp. 59-64

  5. Variations at multiple genes improve interleukin 28B genotype predictive capacity for response to therapy against hepatitis C infection

    AIDS, Vol. 27, Núm. 17, pp. 2715-2724

2012

  1. A common polymorphism in TLR3 confers natural resistance to HIV-1 infection

    Journal of Immunology, Vol. 188, Núm. 2, pp. 818-823

  2. Genetic variability at the TREX1 locus is not associated with natural resistance to HIV-1 infection

    AIDS, Vol. 26, Núm. 11, pp. 1443-1445

  3. Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)-coinfected patients using HCV genotype, IL28B variations, and HCV-RNA load

    Journal of Hepatology, Vol. 56, Núm. 4, pp. 788-794

2011

  1. Different distributions of hepatitis C virus genotypes among HIV-infected patients with acute and chronic hepatitis C according to interleukin-28B genotype

    HIV Medicine, Vol. 12, Núm. 8, pp. 487-493

  2. Low-density lipoprotein receptor genotyping enhances the predictive value of IL28B genotype in HIV/hepatitis C virus-coinfected patients

    AIDS, Vol. 25, Núm. 11, pp. 1415-1420

2010

  1. Modeling the probability of sustained virological response to therapy with pegylated interferon plus ribavirin in patients coinfected with hepatitis C virus and HIV

    Clinical Infectious Diseases, Vol. 51, Núm. 10, pp. 1209-1216

  2. Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus

    Clinical Infectious Diseases, Vol. 51, Núm. 7, pp. 788-795

2008

  1. Vitamin D receptor gene haplotypes and susceptibility to HIV-1 infection in injection drug users

    Journal of Infectious Diseases, Vol. 197, Núm. 3, pp. 405-410